Novel Titanocene Y derivative with albumin affinity exhibits improved anticancer activity against platinum resistant cells

Sergio Gomez-Lopez,Rosario Serrano,Boiko Cohen,Isabel Martinez-Argudo,Laura Lopez-Sanz,Marta Carmen Guadamillas,Raul Calero,Maria Jose Ruiz
DOI: https://doi.org/10.1016/j.jinorgbio.2024.112520
IF: 4.336
2024-05-01
Journal of Inorganic Biochemistry
Abstract:The antitumor activity of Ti(IV)-based compounds put them in the spotlight for cancer treatment in the past, but their lack of stability in vivo due to a high rate of hydrolysis has hindered their development as antitumor drugs. As a possible solution for this problem, we have reported a synthesis strategy through which we combined a titanocene fragment, a tridentate ligand, and a long aliphatic chain. This strategy allowed us to generate a titanium compound (Myr-Ti) capable of interacting with albumin, highly stable in water and with cytotoxic activity in tumor cells[1]. Following a similar strategy, now we report the synthesis of a new compound (Myr-TiY) derived from titanocene Y that shows antitumoral activity in a cisplatin resistant model with a 50% inhibitory concentration (IC50) of 41-76 μM. This new compound shows high stability and a strong interaction with human serum albumin. Myr-TiY has a significant antiproliferative and proapoptotic effect on the tested cancer cells and shows potential tumor selectivity when assayed in non-tumor human epithelial cells being more selective (1.3-3.8 times) for tumor cells than cisplatin. These results lead us to think that the described synthesis strategy could be useful to generate compounds for the treatment of both cisplatin-sensitive and cisplatin-resistant cancers.
biochemistry & molecular biology,chemistry, inorganic & nuclear
What problem does this paper attempt to address?